Aditya Juloori
Papers
5
Total Citations
95
H-Index
4
About
Dr. Aditya Juloori is a leading oncologist and clinical researcher whose work is reshaping the treatment landscape for human papillomavirus-positive (HPV+) oropharyngeal cancer. His primary research focuses on integrating immunotherapy with response-adaptive, de-escalated treatment strategies to reduce toxicity without compromising survival. Dr. Juloori’s major contributions include pioneering the OPTIMA II trial, which demonstrated that neoadjuvant nivolumab, nab-paclitaxel, and carboplatin followed by risk/response-adaptive locoregional therapy can safely de-intensify treatment for HPV+ oropharyngeal cancer. He has also led the TARGET-HPV trial, evaluating neoadjuvant HPV16-specific arenavirus-based immunotherapy, and has advanced the use of circulating tumor HPV DNA (ctHPV-DNA) as a noninvasive biomarker for guiding de-escalation. His work has garnered significant attention, with key papers accumulating over 95 citations. Notably, his 2024 study on neoadjuvant nivolumab plus chemotherapy with response-adaptive therapy has been cited 45 times, underscoring its impact. Dr. Juloori’s research promises to transform care by preserving functional outcomes and quality of life for patients with this favorable-prognosis cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5